Abstract: Peripheral artery disease is a common complication among dialyzed patients. Since Vitamin K antagonists promote metastatic calcifications and these are the main determinants of vascular damage, we investigated their role in the development of lower limb ulcers in dialyzed patients. We retrospectively enrolled 316 dialyzed patients, aged 68 ± 15 years, 65% male, 32% diabetic, 43% with ischemic heart disease and followed them for 36 ± 25 months. 60 patients assumed Vitamin K antagonists: they were older, with a higher prevalence of heart disease, at greater risk of death and they developed more ulcers and underwent more lower limb amputations compared to the rest of our cohort. Peripheral artery disease, Vitamin K antagonists and diabetes were independent risk factors for foot lesions. In addition, Vitamin K antagonists were also an independent risk factor for death. Vitamin K antagonists are a potent independent risk factor for the development of the uremic foot syndrome and death.
Peripheral artery disease (PAD) affects 15 to 40% of hemodialysis patients (1) and correlates with cardiac and all-cause mortality; foot ulcerations and lower limb amputation represent the eventual consequences of PAD. Since foot ulcers occur in about 25% of diabetic patients (2) , the definition "diabetic foot syndrome" is largely used to identify the condition characterized by ulcers, with or without infection, gangrene and amputation of lower limbs. Hemodialysis is associated with a burden of foot ulceration and amputation (3, 4) not only for the high prevalence of diabetes among dialysis patients but also for the interaction between the traditional and uremia-related cardiovascular risk factors.
Among uremia-related metabolic dysfunctions, vascular calcifications play a pivotal role in vascular damage (5, 6) . Vascular calcification is an active process, regulated by several inducing or inhibiting proteins and most of these agents are Vitamin K-dependent proteins, requiring Vitamin K as cofactor to achieve their full biological activity (7) .
As a consequence, Vitamin K antagonists (Vit K-Ant) are associated with metastatic, coronary and aortic valve calcifications, in non renal and renal patients (8, 9) .
While the association between Vit K-Ant and cardiac calcifications is now recognized, no studies have investigated the role of the oral anticoagulation therapy (OAT) in the development of lower limb ulcers in dialyzed patients.
The aim of our retrospective study was, first, to evaluate the relationship between Vitamin K antagonist therapy and the occurrence of ulcers and, second, to investigate the correlation between Vitamin K antagonists and death in the uremic population.
PATIENTS AND METHODS

Study population
We conducted a retrospective study on prevalent and incident maintenance hemodialysis patients attending a single university-based dialysis center, between January 2005 and December 2010 and followed until December 2011. Only adult (>18 years) subjects, receiving hemodialysis three times a week for a minimum of six months were enrolled.
At the time of the initiation of hemodialysis in our Centre, every patient signed an "informed consent" to allow the use of clinical and anamnestic data in anonymous form for scientific publications.
Data collection
Baseline demographic and clinical data as well as comorbidities such as diabetes mellitus, neoplasms and cardiac disease, were obtained by reviewing medical notes, clinical summaries and patient interviews. Diabetic status was defined as the current or past use of oral hypoglycemic agents or insulin; coronary artery ischemic disease was defined by history of myocardial infarction or angina and/or instrumental evidence of ischemic heart disease (electrocardiogram, echocardiogram, stress test, angiography/angioplasty, coronary artery bypass grafting). PAD was defined clinically as having signs/symptoms such as walking limb pain (claudicatio intermittens) and ischemic lesions, or through instrumental examinations such as Doppler-ultrasonography and angiography, or through anamnestic data such as previous angioplasty or surgical revascularization procedures. As signs of lower limb ischemia, we considered foot ulcer as the condition characterized by an interruption of epithelium, with or without soft tissue infection, ischemia or gangrene and amputation of lower limb extremity upon or below the malleoli.
When oral Vit K-Ant were prescribed, either as coumarin derivatives, acenocoumarol or dicoumarol, we registered the duration of therapy and its indications categorized as cardiologic, prevention of dialysis access thrombosis, previous arterious or venous thromboembolism and systemic diseases. To evaluate the relationship between OAT and uremic foot we considered only the ulcers that occurred at least 3 months after the initiation of Vit K-Ant. Patients who developed ulcers within 3 months from the beginning of OAT were excluded from the study as well as patients who already had ulcers before the starting of dialysis.
The primary endpoint was the occurrence of chronic limb ulcers and amputation of lower limb, upon or below the malleoli; the secondary endpoint was death for all causes.
Statistical analysis
Data are presented as mean and standard deviation or percentages for categorical variables. Comparison between groups was performed using Fisher's exact test for categorical variables and Mann-Whitney U-test for non-normally distributed continuous variables between two groups. The impact of PAD, diabetes, cardiac disease, OAT, serum parathyroid hormone (PTH) levels, hemodialysis duration and age on occurrence of foot ulcers and death, was assessed by multiple regression analysis. Kaplan-Meier method and log-rank test were used to examine the impact of Vit K-Ant on ulcer, amputation and death occurrence. Statistical analyses were performed using the STATISTICA 6.0 software (StatSoft Inc, Tulsa, OK, USA) and Prism 6.00 software (GraphPad software, La Jolla, CA, USA) using a two-sided type I error rate of 0.05. P-values less than 0.05 were considered statistically significant.
RESULTS
Of 445 potential participants, 316 met the inclusion criteria. 129 patients were excluded: 107 received hemodialysis for less than 6 months (91 died and 16 received renal transplantation), eight were lost to follow up and 14 patients developed lower limb ulcers before starting Vit K-Ant therapy.
Baseline characteristics are summarized in Table 1 . 43% of patients had coronary artery disease, 32% were diabetic and diabetes mellitus accounted for 20% of the causes of end stage renal disease.
Peripheral artery disease was present in more than half of subjects and about 10% received major vascular surgery and angioplasty; chronic foot ulcers and lower limb amputation occurred in 88 (28%) and 30 (10%) patients, respectively. The mean follow-up was 36 ± 25 months. Twenty (67%) and 10 (33%) patients received amputation below and above the malleoli, respectively; 25 (83%) and five (17%) patients received mono and bilateral amputation, respectively. Ulcers occurred in 55 (54%) diabetic and 33 (15%) non-diabetic subjects, while amputation occurred in 22 (22%) diabetic and eight (4%) non-diabetic subjects, respectively (P < 0.01). 
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Sixty (19%) patients assumed oral Vit K-Ant, 30 (50%) for cardiac diseases, 16 (27%) to maintain the patency of a permanent dialysis central venous catheter, 10 (17%) for previous artero-venous thromboembolism, four (6%) for systemic diseases. The main vintage of Vit K-Ant therapy was 35 ± 26 months and 50 (83%) patients assumed it for more than 12 months.
Patients assuming Vit K-Ant, compared with patients not assuming it, showed a statistically significant higher prevalence of PAD (78 vs 47%), ulcers (64 vs. 19%) and amputation (18 vs. 7%) ( Tables 2,3 ). Although diabetic patients were more likely to undergo amputation or developing ulcers, Vitamin K antagonist therapy did not differ between diabetic and non-diabetic patients, as shown in Table 4 .
Overall we observed 10 and 15 major bleeding events (defined as bleeding episodes requiring packed red blood cell transfusion) in six patients assuming OAT and 12 patients not under Vit K-Ant therapy, respectively (P = NS, Table 3 ). We found a statistically significant difference in bleeding sites between the two groups in respect to urinary tract and muscular bleeding (Table 3) . During the followup period there were 38 and 82 thromboembolic events in 26 patients on OAT and 68 patients not assuming oral anticoagulants, respectively (P < 0.05, Table 3 ). We observed a higher prevalence of venous thrombosis in patients assuming Vit K-Ant while peripheral artery thrombosis was more common in patients not assuming Vit K-Ant (Table 3) .
The Kaplan-Meier curve showed that patients assuming Vit K-Ant had a higher risk of developing ulcers (Fig. 1, A) (HR 3.973, 95% CI 3.763 to 12.61, P < 0.001), as well as undergoing lower limb amputation (Fig. 1, B) (HR 2.482, 95% CI 1.256 to 7.821, P = 0.0147).
At the end of the follow-up, 158 (50%) patients died: 46 (29%) of cardiac disease, 33 (21%) of complications of PAD, 30 (19%) of cachexia, 29 (19%) of infections, 10 (6%) of neoplasms and 10 (6%) of other causes. Mortality was higher in patients assuming OAT (Fig. 1, C. ) (HR 1.663, CI 1.119 to 2.473, P = 0.0119).
In the multiple regression model, PAD (β = 0.35), Vit K-Ant (β = 0.31), diabetes (β = 0.26) and negatively PTH (β = À0.09) were independent risk factors for foot ulcers (Table 5) .
Finally, age (β = 0.22), PAD (β = 0.16), CAD (β = 0.16) and Vit K-Ant (β = 0.12) resulted as statistically significant predictors of death (Table 6) .
DISCUSSION
This study demonstrates that lower limb ulceration is a common complication among dialyzed patients (1,10) ; it is associated with traditional and uremia-related risk factors and correlates with cardiovascular and all-cause mortality. In our population PAD occurs in a higher percentage, probably because of the instrumental criteria that detects the earliest stage of the disease.
Diabetes mellitus, the main determinant of foot ulceration in patients with PAD, is responsible for 20 to 45% of renal replacement therapy in the Western world (11) , and for about 20% in our sample, while 32% of our patients were diabetic. However, advanced renal disease is associated with PAD and its complications, independently of the diabetic status. It was demonstrated that foot ulceration and amputation account for up to 30% and 15%, respectively, among diabetic dialyzed patients, compared to 15% and 7% among diabetic non dialyzed-ones (3, 4) . In some studies, the risk of amputation among dialyzed patients is about 10 times higher than in diabetic population (12) . The high correlation between foot ulcers and dialysis is also confirmed by the temporal association between ulcer appearance and the initiation of renal replacement therapy (1,13). Finally, among renal patients the post-amputation mortality is about 16% in contrast to 6% of subjects with normal renal function (4, 14) . Foot complications in diabetic patients, regardless of the main cause that determined them, either neuropathy or vasculopathy, are defined as diabetic foot syndrome (15) . In light of these considerations, we propose to define as "uremic foot syndrome" the status characterized by the presence of PAD, foot ulcers, with or without soft tissue infection, ischemia, gangrene and the amputation of lower 
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limb extremity among dialyzed subjects, independently of the presence of diabetes. In addition to the traditional risk factors (hypertension, smoking, hyperlipemia, diabetes), the burden of vascular damage among renal patients is increased by uremia-related risk factors: inflammation, malnutrition and vascular calcifications. In the uremic milieu, the calcification process occurs in the medial tunica of the vessels (16) in contrast to the intimal calcification, typical of atherosclerosis. The calcified medial tunica increases arterial stiffness, causing higher cardiovascular morbidity and mortality (5). Metastatic calcification is mainly due to the calcium-phosphorus and PTH-Vitamin D imbalance; it is an active cell-mediated process, regulated by several activating and inhibiting proteins. Most of these agents are Vitamin K-depending proteins: they need to undergo post translational γ-glutamyl carboxilation to achieve full biological activity and this reaction requires Vitamin K as a cofactor (7). One of the most studied agents is the Matrix Gla Protein (MGP) a potent inhibitor of tissue mineralization (17) either by directly inhibiting calcium precipitation and by antagonizing calcification inductors. It has been confirmed in human pathology that therapy with Vit K-Ant induces vascular calcifications: Schugers analyzed 45 aortic valves obtained from cardiac replacement and found that the calcified area was larger in patients previously treated with Vit K-Ant (18). Koos first confirmed a higher coronary and valvular calcium score, detected by multislice computed tomography, in patients assuming oral anticoagulation therapy and then correlated serum levels of MGP with aortic valve calcification (8, 19) . More recently, in a prospective observational study, Weijs found that patients assuming Vit K-Ant for atrial fibrillation showed higher coronary calcium score, that was also proportional to the duration of the therapy (20) . Finally, Rennenberg found a direct correlation between the femoral artery calcification score, detected by X-rays, and the inactive form of MGP in patients assuming coumarin derivatives, compared to a healthy control group (21) .
Dialyzed patients show Vit K deficiency: Steiber et al. (22) found that 97% of patients with chronic kidney disease had subclinical Vitamin K deficiency, due either to the reduced dietary intake and the widespread use of Vit K-Ant. Regarding dietary intake, Vit K is distinguished in phylloquinone (Vit K1), in leafy green vegetable and menaquinone (Vit K2) in cheese (7), foods not recommended in dialyzed patients, because of the potassium and phosphorus content, respectively. Regarding Vit K-Ant therapy, 20 to 25% of HD patients are prescribed coumarin derivatives (23) , with two patterns of anticoagulation therapy: (i) a full-intensity schedule (international normalized ratio, INR 2 to 3) for cardiologic and hematologic indications, according to the recommendations for general population, despite the higher risk of bleeding; and (ii) a low-intensity schedule (INR 1.4 to 1.9) for the prevention of access thrombosis (central venous catheters and prosthetic grafts). Our experience is consistent with the literature, with 19% of patients assuming oral anticoagulation therapy, 50% for cardiac diseases and 25% to maintain vascular access patency.
The relationship between Vit K-Ant and the prevalence and extent of aortic valve and coronary calcifications has been recently recognized also in dialyzed patients. Holden and colleagues demonstrated that dialyzed subjects assuming OAT were more likely to have severe aortic valve calcifications, detected by echocardiographic assessment (9) . They also found an association between the lifetime months of warfarin exposure and the severity of calcification. More recently, in a longitudinal study, Mac-Way found that aortic stiffness increases in dialyzed patients assuming Vit K-Ant and in dialyzed patients with intrinsic vitamin K deficiency (24) .
Moving from these biological, experimental and epidemiological premises, we hypothesized and confirmed the relationship between the Vit K-Ant and the uremic foot syndrome. We found that dialyzed patients assuming Vit K-Ant showed a higher risk of foot ulcers and amputation, independently of other conditions such as age, diabetes and cardiac disease. In addition, patients presented a higher risk of death, independently of other traditional risk factors. Since we did not observe life-threatening bleedings, we could conclude that the excess risk of death is due to cardiovascular damage. Of course, the multiple comorbidities of dialysis patients and their frailty, perhaps, overcame the benefits expected by OAT and did not protect them even by thromboembolic events. This is in accordance with Mac-Way's results, who observed a 2.5-fold increase in risk of death in patients assuming warfarin compared to the control group, in the absence of deaths related to bleeding (24) . To investigate the temporal relationship between OAT and ulcers, we considered only ulcers that occurred after 3 months of Vit K-Ant therapy, even if we did not correlate the intensity of exposure to OAT with the severity of the lesions. Similarly to Mac-Way's experience, our patients were on OAT for an average of 35 months, a time longer than the 3 to 8 weeks required in experimental animal models to induce vitamin K depletion and vascular damage (25) . Since it seems that coumarin derivatives induce
154
A De Mauri et al.
vascular damage in a time and dose-dependent manner in animal and human studies (9, 20) , the real impact of Vit K-Ant depends on the interactions of various pro-calcifying factors. Finally, we evaluated a possible role of the calcium-phosphorus-PTH imbalance in the uremic foot syndrome and death, and we found that PTH levels were negatively associated with ulcers at the multilinear regression analysis. Other studies reported a negative correlation between PTH and cardiac calcifications; it has been hypothesized either that the treatment of hyperparathyroidism could influence the analysis or that the low-bone turnover state induces the preferential deposition of calcium in extraskeletal sites, worsening vascular calcifications.
Our study has several limitations. First, it is a monocentric retrospective study and our data need to be confirmed by prospective clinical trials. Second, we hypothesized that the main determinant of the uremic foot syndrome are vascular calcifications, but we did not score it by means of instrumental tools. Third, we supposed that the physiopathological and biological link between uremic foot and Vit K-Ant is the impaired activity of Vitamin K depending proteins, but we did not estimate the serum levels of these proteins or Vitamin K itself.
On the other hand our work shows several important findings. First, to our knowledge, this is the first time the term "uremic foot syndrome" is used, in the light of the epidemiological and biological evidence in dialysis literature. Second, this is the first study correlating Vitamin K Antagonist therapy with a clinical endpoint (foot ulcers and amputation), with very high human and social costs. Third, we found that, among uremic patients, coumarin derivatives are associated with a higher risk of death, independently of other risk factors.
CONCLUSIONS
Our study demonstrates that the "uremic foot" is a common complication among dialyzed patients and an important cause of death and is a concern for nephrologists who should strive to early diagnose and treat peripheral artery disease.
Vitamin K antagonists are an independent risk factor for the development of uremic foot syndrome and death in dialyzed patients. Further studies are needed to clarify the pros and cons of OAT and other anticoagulation agents could be considered for dialyzed patients.
